Interest in the emerging field of psilocybin – the active ingredient in magic mushrooms – has grown in recent years with various research demonstrating that psychedelics-assisted therapy holds great ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to ...
An experimental psychedelic tryptamine combined with supportive therapy is associated with improvements in moderate to severe major depressive disorder (MDD), new research suggests. Top-line results ...
TipRanks on MSN
Entropy Neurodynamics secures $847,186 R&D tax refund to advance psychedelic therapy trials
Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics has received an $847,186 cash refund under Australia’s R&D Tax ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing ...
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. CYBN signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. MSSTF for an ...
Tryptamine is focusing on ‘precision psychedelics’ to overcome key limitations of orally administered psilocybin. Interest in the emerging field of psilocybin – the active ingredient in magic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback